NuCana’s potent anti-cancer completed Phase I/II

Good news just keeps on coming from ASCO Annual Meeting. Edinburgh-based NuCana presented in two abstracts the last data from Acelarin, the company’s first anti-cancer agent, produced on its ProTide developing platform.

ProTides are NuCana’s new class of anti-cancer agents, which are specifically designed to overcome key cancer resistance mechanisms that severely limit the action and effectiveness of many commonly prescribed anti-cancer drugs. ProTide’s innovative technology enables the addition of a phosphoramidate moiety to the commonly used anti-cancer nucleoside analogs.

This transformation results in a significantly more active agent being generated within the cancer cells, with much less metabolic degradation and, therefore, superior efficacy and a more favorable safety profile. Acelarin, NuCana’s first ProTide candidate, aims to validate this concept in its soon-to-come Phase III clinical trial.

Structure of ProTide. Source: NuCana

Structure of ProTide. Source: NuCana

For the moment, Acelarin’s Phase I/II study reached its primary objective, having established the recommended Phase II dose, and an expansion stage further assessed the efficacy and safety profile.

NuCana’s approach may be worth a decent amount of money, although it is not the only one to think so. Pharmasset already used the same method to develop a Hepatitis C treatment that Gilead Sciences happily bought for €10.3Bn. The British company, however, has an exclusive license to employ the ProTide’s technology in cancer. A great advantage that might be the reason of NuCana’s €51M Series B last year.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.